Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 134

Showing 1-25 of 134 citing articles:

Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies
Alessia Catalano, Domenico Iacopetta, Jessica Ceramella, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 616-616
Open Access | Times Cited: 282
Anticancer drug resistance: An update and perspective
Ruth Nussinov, Chung‐Jung Tsai, Hyunbum Jang
Drug Resistance Updates (2021) Vol. 59, pp. 100796-100796
Open Access | Times Cited: 239
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez‐Ruiz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 166
Polymer- and lipid-based nanocarriers for ocular drug delivery: Current status and future perspectives
Haijie Han, Su Li, Mingyu Xu, et al.
Advanced Drug Delivery Reviews (2023) Vol. 196, pp. 114770-114770
Open Access | Times Cited: 130
Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery
Saquib Waheed, Zhibin Li, Fangyingnan Zhang, et al.
Journal of Nanobiotechnology (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 105
Advances of medical nanorobots for future cancer treatments
Xiangyi Kong, Peng Gao, Jing Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 93
Advances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Andaleeb Sajid, Hadiar Rahman, Suresh V. Ambudkar
Nature reviews. Cancer (2023) Vol. 23, Iss. 11, pp. 762-779
Closed Access | Times Cited: 69
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents
Enrique Domínguez‐Álvarez, Bálint Rácz, Małgorzata Anna Marć, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100844-100844
Open Access | Times Cited: 66
Current advance of nanotechnology in diagnosis and treatment for malignant tumors
Bilan Wang, Shiqi Hu, Yan Teng, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Flower-like Nanozyme with Highly Porous Carbon Matrix Induces Robust Oxidative Storm against Drug-Resistant Cancer
Yuxin Xing, Lin Li, Yuhua Chen, et al.
ACS Nano (2023) Vol. 17, Iss. 7, pp. 6731-6744
Closed Access | Times Cited: 47
Role of nanoparticles in enhancing chemotherapy efficacy for cancer treatment
Huma Ghazal, Aimen Waqar, Faiza Yaseen, et al.
Next Materials (2024) Vol. 2, pp. 100128-100128
Open Access | Times Cited: 21
Fenton/Fenton-like metal-based nanomaterials combine with oxidase for synergistic tumor therapy
Wei Cao, Mengyao Jin, Kang Yang, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 72
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies
Hanxin Liu, Huifang Zhao, Yu Sun
Seminars in Cancer Biology (2021) Vol. 86, pp. 769-781
Open Access | Times Cited: 67
Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer
Ruixue Yang, Mei Yi, Bo Xiang
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 54
Long non-coding RNAs (lncRNAs) signaling in cancer chemoresistance: From prediction to druggability
Giasemi C. Eptaminitaki, Dimitris Stellas, Benjamin Bonavida, et al.
Drug Resistance Updates (2022) Vol. 65, pp. 100866-100866
Closed Access | Times Cited: 49
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment
Junnan Li, Lipeng Zhu, Hang Fai Kwok
Drug Resistance Updates (2022) Vol. 66, pp. 100904-100904
Closed Access | Times Cited: 48
Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials
Syed Nasir Abbas Bukhari
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 866-866
Open Access | Times Cited: 46
Recent Progress in Carrier‐Free Nanomedicine for Tumor Phototherapy
Yingtao Zhong, Yi Cen, Lin Xu, et al.
Advanced Healthcare Materials (2022) Vol. 12, Iss. 4
Closed Access | Times Cited: 46
Folate receptor-mediated delivery of mitoxantrone-loaded solid lipid nanoparticles to breast cancer cells
Andreia Granja, Cláudia Nunes, C. T. Sousa, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113525-113525
Open Access | Times Cited: 45
Nanomedicine Combats Drug Resistance in Lung Cancer
Xiuli Zheng, Xiao-Hai Song, Guonian Zhu, et al.
Advanced Materials (2023) Vol. 36, Iss. 3
Closed Access | Times Cited: 30
Recent advances in access to overcome cancer drug resistance by nanocarrier drug delivery system
Xiangyu Sun, Ping Zhao, Jierou Lin, et al.
Cancer Drug Resistance (2023) Vol. 6, Iss. 2, pp. 390-415
Open Access | Times Cited: 29
Photo‐Enhanced Synergistic Induction of Ferroptosis for Anti‐Cancer Immunotherapy
Yang Zhou, Chen Kang, Wing Kak Lin, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 27
Open Access | Times Cited: 28
Multifunctional nano MOF drug delivery platform in combination therapy
Dongwei Ma, Gang Wang, Jing-Sheng Lu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115884-115884
Closed Access | Times Cited: 24
Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance
Jianing Gong, Taoran Shi, Jinfeng Liu, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 161, pp. 114505-114505
Open Access | Times Cited: 21
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy
Y. Qin, Shisong Han, Yahan Yu, et al.
Liver International (2024) Vol. 44, Iss. 8, pp. 1808-1831
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top